Pressemeldinger

Bristol-Myers Squibb får positiv CHMP-vurdering for Daklinza® (daclatasvir) for behandling av kronisk hepatitt C i EU

30-06-2014 14:00 CEST Bristol-Myers Squibb

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

17-06-2014 13:58 CEST Biogen Idec Norway AS − DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate – − Positive Results Set Stage for Regulatory Filings –

Hodebunnsproblemer

09-06-2014 21:41 CEST Odd S. Nielsen Frisørsalong A/S Det å finne balanse i både å være ren og ha en fungerende/tilstedeværende syrekappe (hudens egen beskyttelse) er viktig. Alt for ofte blir den naturlige balansen og motstandsdyktigheten redusert på grunn av overvasking. Dette provoser frem problemer.

02-06-2014 14:00 CEST Bristol-Myers Squibb

BIOGEN IDEC ANNOUNCES OFFICIAL PARTNERSHIP WITH SAILING SCLEROSIS’ “OCEANS OF HOPE” TO GLOBALLY CHANGE PERCEPTIONS OF MS

28-05-2014 10:51 CEST Biogen Idec Norway AS - Global Project Uses Sailing to Empower People Living with Multiple Sclerosis -

CHMP ADOPTS POSITIVE OPINION FOR PLEGRIDYTM (PEGINTERFERON BETA-1A) AS A TREATMENT FOR MULTIPLE SCLEROSIS IN THE EUROPEAN UNION

28-05-2014 10:41 CEST Biogen Idec Norway AS – European Commission Decision on Marketing Authorization Anticipated in 2H of 2014 – – PLEGRIDY May Offer People with MS a Combination of Efficacy, Favorable Safety Profile and Low Frequency Dosing Schedule –

 In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy® (ipilimumab)

16-05-2014 10:17 CEST Bristol-Myers Squibb

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase 1b                                             Non-Small Cell Lung Cancer Trials

16-05-2014 10:13 CEST Bristol-Myers Squibb

Bristol-Myers Squibb Announces Two- and Three-Year Survival Data for Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Advanced Melanoma Cohort of a Phase 1b Study

16-05-2014 09:48 CEST Bristol-Myers Squibb • Across doses (n=107), 48% and 41% of this heavily pre-treated patient population that received nivolumab as a single agent was alive at two and three years, respectively • Spectrum, frequency and severity of treatment-related adverse events from this study were consistent with those initially reported for these patients in prior publications

Bristol- Myers Squibb presenterer data for et legemiddel i perorale kombinasjoner på tvers av ulike genotyper av hepatitt C på The International Liver Congress

24-03-2014 15:46 CET Bristol-Myers Squibb